OS Therapies Inc’s (NYSE:OSTX) Lock-Up Period Will Expire on January 28th

OS Therapies’ (NYSE:OSTX) lock-up period is set to expire on Tuesday, January 28th. OS Therapies had issued 1,600,000 shares in its initial public offering on August 1st. The total size of the offering was $6,400,000 based on an initial share price of $4.00. After the expiration of OS Therapies’ lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on OSTX. Maxim Group boosted their price objective on OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, January 16th. D. Boral Capital reiterated a “buy” rating and issued a $20.00 price target on shares of OS Therapies in a research report on Wednesday, January 15th.

OS Therapies Price Performance

OSTX opened at $2.69 on Friday. The stock’s fifty day moving average is $3.37. OS Therapies has a fifty-two week low of $1.58 and a fifty-two week high of $7.00.

Insider Activity at OS Therapies

In other news, major shareholder Shalom Auerbach sold 16,720 shares of OS Therapies stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $6.74, for a total transaction of $112,692.80. Following the transaction, the insider now owns 2,531,211 shares in the company, valued at approximately $17,060,362.14. The trade was a 0.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Hedge Funds Weigh In On OS Therapies

A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC acquired a new stake in shares of OS Therapies Inc (NYSE:OSTX) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.